MedTrace Logo

Hemorrhage Stroke Decision Making Model Based Deep Learning (BrainHemoAI System)

NCT07570680 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 7100

Last updated 2026-05-06

No results posted yet for this study

Summary

Although hemorrhagic stroke also has the characteristics of high mortality and disability rates, and constitutes a major public health problem worldwide, there is a relative lack of in-depth research teams for hemorrhagic stroke in China. The current preoperative imaging evaluation of spontaneous cerebral hemorrhage is still limited to the traditional Tada formula, and there are subjective differences in diagnosis among different doctors, making it difficult to achieve homogenization in clinical decision-making. Hemorrhagic stroke is a common and frequently occurring disease in Jiangxi Province. Therefore, establishing a new diagnosis and treatment system focused on hemorrhagic stroke can not only fill the research gap in this field in China, improve the accuracy and homogeneity of hemorrhagic stroke diagnosis and treatment, but also promote related research progress to reduce the mortality and disability rates of this disease and improve the clinical prognosis of patients.

Conditions

  • Hemorrhage Stroke

Interventions

DIAGNOSTIC_TEST

Large language model

Automatical diagnosis, treatment decision-making, and risk prediction after spontaneous intracerebral hemorrhage via a trained deep learning larger language model.

Sponsors & Collaborators

  • First Affiliated Hospital of Gannan Medical University

    collaborator OTHER

  • Zhejiang University

    collaborator OTHER

  • Ganzhou City People's Hospital

    collaborator OTHER

  • The First People's Hospital of Xiushui

    collaborator OTHER

  • Jiujiang No.1 People's Hospital

    collaborator OTHER

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • Second Affiliated Hospital of Nanchang University

    lead OTHER

Eligibility

Min Age
8 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2026-08-01
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07570680 on ClinicalTrials.gov